Cysoni
Phase 1- Indications
- Heart failure
Company intelligence / Profile preview
Ceryx Medical
Cardiff, Wales, United Kingdomceryxmedical.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company’s lead program Cysoni has entered its first human clinical trial for heart failure. Preclinical data suggest the device can restore cardiac performance by mimicking natural physiological rhythms absent in heart failure patients. No published clinical results yet.
- Therapeutic areas
- CardiovascularEndocrinologyNeurology
- Modalities
- Device (Bioelectronic medical device)Analogue electronics-based therapy (biomimetic artificial neurons and neural networks)
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ceryx Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceryx Medical.